EA201990106A1 - Режим приема селективного модулятора рецептора прогестерона (sprm) - Google Patents
Режим приема селективного модулятора рецептора прогестерона (sprm)Info
- Publication number
- EA201990106A1 EA201990106A1 EA201990106A EA201990106A EA201990106A1 EA 201990106 A1 EA201990106 A1 EA 201990106A1 EA 201990106 A EA201990106 A EA 201990106A EA 201990106 A EA201990106 A EA 201990106A EA 201990106 A1 EA201990106 A1 EA 201990106A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- uterine fibroids
- uterine
- myomas
- sprm
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к фармацевтической композиции, содержащей антагонист рецептора прогестерона, а именно (11β,17β)-17-гидрокси-11-[4-(метилсульфонил)фенил]-17-(пентафторэтил)эстра-4,9-диен-3-он, для лечения и/или профилактики фибромиом матки (миом, лейомиом матки), которую вводят пациенту с диагнозом фибромиомы матки, следуя конкретному режиму приема. Дополнительно изобретение относится к способу лечения фибромиом матки (миом, лейомиом матки) и/или для уменьшения размера фибромиом матки (миом, лейомиом матки) и симптомов, связанных с фибромиомами матки, следуя конкретному режиму приема, а также лечения тяжелых менструальных кровотечений (ТМК).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15001475 | 2015-05-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201990106A1 true EA201990106A1 (ru) | 2019-05-31 |
EA036237B1 EA036237B1 (ru) | 2020-10-16 |
Family
ID=53180494
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990106A EA036237B1 (ru) | 2015-05-18 | 2016-05-17 | Режим приема селективного модулятора рецептора прогестерона (sprm) |
EA201792524A EA035567B1 (ru) | 2015-05-18 | 2016-05-17 | Режим приема селективного модулятора рецептора прогестерона (sprm) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792524A EA035567B1 (ru) | 2015-05-18 | 2016-05-17 | Режим приема селективного модулятора рецептора прогестерона (sprm) |
Country Status (19)
Country | Link |
---|---|
US (3) | US20180155388A1 (ru) |
EP (2) | EP3417863A1 (ru) |
JP (2) | JP2018515551A (ru) |
KR (1) | KR20180004814A (ru) |
CN (2) | CN107635562A (ru) |
AU (1) | AU2016262826A1 (ru) |
BR (1) | BR112017024627A2 (ru) |
CA (1) | CA2986064A1 (ru) |
CL (1) | CL2017002920A1 (ru) |
EA (2) | EA036237B1 (ru) |
HK (1) | HK1245118A1 (ru) |
IL (1) | IL255451A0 (ru) |
MA (2) | MA46298A (ru) |
MX (1) | MX2017014844A (ru) |
PH (1) | PH12017502100A1 (ru) |
SG (1) | SG10201910441PA (ru) |
TN (1) | TN2017000482A1 (ru) |
TW (1) | TW201707708A (ru) |
WO (1) | WO2016184863A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018515551A (ja) * | 2015-05-18 | 2018-06-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 選択的プロゲステロン受容体モジュレーター(sprm)レジメン |
EP3214092A1 (en) * | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one |
EP3384913A1 (en) * | 2017-04-03 | 2018-10-10 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulators and stabilized estrogen level in patient |
EP3701951A4 (en) * | 2017-10-26 | 2020-09-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
JP2001520820A (ja) * | 1997-02-03 | 2001-10-30 | エムシーアイ・ワールドコム・インコーポレーテッド | 通信システム構造 |
DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
EP1624848A4 (en) | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
PT2163562E (pt) | 2005-06-21 | 2013-12-19 | Xoma Us Llc | Anticorpos de ligação a il 1 beta e respectivos fragmentos |
ES2586741T3 (es) | 2008-04-30 | 2016-10-18 | Telefonaktiebolaget L M Ericsson (Publ) | Red de auto-retorno en LTE |
EP2123279A1 (de) * | 2008-05-14 | 2009-11-25 | Bayer Schering Pharma Aktiengesellschaft | Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen |
DE102009034362A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
ES2672509T3 (es) * | 2012-09-28 | 2018-06-14 | Aska Pharmaceutical Co., Ltd. | Forma polimórfica cristalina de acetato de ulipristal |
MX2015004821A (es) * | 2012-11-02 | 2015-08-14 | Repros Therapeutics Inc | Metodos y composiciones para tratar condiciones dependientes de la progesterona. |
KR20140077499A (ko) * | 2012-12-14 | 2014-06-24 | 에스케이하이닉스 주식회사 | 저항 변화 메모리 장치 및 그 제조방법 |
WO2014167510A2 (en) * | 2013-04-10 | 2014-10-16 | Preglem Sa | Progesteron receptor modulators for use in the therapy of uterine fibroids |
EP2983671B1 (en) * | 2013-04-11 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
JP2018515551A (ja) | 2015-05-18 | 2018-06-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 選択的プロゲステロン受容体モジュレーター(sprm)レジメン |
EP3384913A1 (en) * | 2017-04-03 | 2018-10-10 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulators and stabilized estrogen level in patient |
-
2016
- 2016-05-17 JP JP2017560210A patent/JP2018515551A/ja active Pending
- 2016-05-17 MA MA046298A patent/MA46298A/fr unknown
- 2016-05-17 US US15/575,088 patent/US20180155388A1/en not_active Abandoned
- 2016-05-17 CA CA2986064A patent/CA2986064A1/en not_active Abandoned
- 2016-05-17 MA MA042103A patent/MA42103A/fr unknown
- 2016-05-17 KR KR1020177035871A patent/KR20180004814A/ko unknown
- 2016-05-17 EP EP18182030.9A patent/EP3417863A1/en not_active Withdrawn
- 2016-05-17 EA EA201990106A patent/EA036237B1/ru not_active IP Right Cessation
- 2016-05-17 SG SG10201910441PA patent/SG10201910441PA/en unknown
- 2016-05-17 EP EP16724020.9A patent/EP3297635A1/en not_active Withdrawn
- 2016-05-17 BR BR112017024627A patent/BR112017024627A2/pt not_active IP Right Cessation
- 2016-05-17 CN CN201680029060.3A patent/CN107635562A/zh active Pending
- 2016-05-17 CN CN202110968810.6A patent/CN113797210A/zh active Pending
- 2016-05-17 TN TNP/2017/000482A patent/TN2017000482A1/en unknown
- 2016-05-17 MX MX2017014844A patent/MX2017014844A/es unknown
- 2016-05-17 EA EA201792524A patent/EA035567B1/ru not_active IP Right Cessation
- 2016-05-17 AU AU2016262826A patent/AU2016262826A1/en not_active Abandoned
- 2016-05-17 WO PCT/EP2016/061037 patent/WO2016184863A1/en active Application Filing
- 2016-05-18 TW TW105115378A patent/TW201707708A/zh unknown
-
2017
- 2017-11-06 IL IL255451A patent/IL255451A0/en unknown
- 2017-11-17 PH PH12017502100A patent/PH12017502100A1/en unknown
- 2017-11-17 CL CL2017002920A patent/CL2017002920A1/es unknown
-
2018
- 2018-04-10 HK HK18104643.3A patent/HK1245118A1/zh unknown
- 2018-12-10 US US16/214,515 patent/US10858388B2/en active Active
-
2019
- 2019-08-12 US US16/538,165 patent/US20190375783A1/en not_active Abandoned
-
2021
- 2021-02-10 JP JP2021019788A patent/JP2021098702A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180155388A1 (en) | 2018-06-07 |
EP3417863A1 (en) | 2018-12-26 |
TN2017000482A1 (en) | 2019-04-12 |
CL2017002920A1 (es) | 2018-05-18 |
CA2986064A1 (en) | 2016-11-24 |
US20190375783A1 (en) | 2019-12-12 |
BR112017024627A2 (pt) | 2018-07-31 |
SG10201910441PA (en) | 2020-01-30 |
MX2017014844A (es) | 2018-02-19 |
JP2021098702A (ja) | 2021-07-01 |
AU2016262826A1 (en) | 2017-11-30 |
US20190211053A1 (en) | 2019-07-11 |
KR20180004814A (ko) | 2018-01-12 |
US10858388B2 (en) | 2020-12-08 |
EA201792524A1 (ru) | 2018-04-30 |
IL255451A0 (en) | 2017-12-31 |
JP2018515551A (ja) | 2018-06-14 |
CN113797210A (zh) | 2021-12-17 |
CN107635562A (zh) | 2018-01-26 |
HK1245118A1 (zh) | 2018-08-24 |
EA035567B1 (ru) | 2020-07-08 |
EP3297635A1 (en) | 2018-03-28 |
MA46298A (fr) | 2019-07-31 |
MA42103A (fr) | 2018-03-28 |
TW201707708A (zh) | 2017-03-01 |
WO2016184863A1 (en) | 2016-11-24 |
PH12017502100A1 (en) | 2018-05-07 |
EA036237B1 (ru) | 2020-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118407T1 (el) | Αντισωματα εξουδετερωσης υποδοχεα προλακτινης και θεραπευτικη χρηση αυτων | |
EA201990106A1 (ru) | Режим приема селективного модулятора рецептора прогестерона (sprm) | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201690556A1 (ru) | Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций | |
EA201990835A2 (ru) | Режимы дозирования антипрогестинов | |
EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
CY1117660T1 (el) | Εξουδετερωτικο αντισωμα υποδοχεα προλακτινης ματ3 και η θεραπευτικη χρηση αυτου | |
CO6491067A2 (es) | Derivados de 17-hidroxi-17-pentafluoretil-estra-4,9(10)-dien-11arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades | |
CU20120175A7 (es) | Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos | |
EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
RU2017101147A (ru) | Терапия стволовыми клетками при патологиях эндометрия | |
EA201790289A1 (ru) | Оксазолидин-2-онпиримидиновые производные | |
CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
EA201491614A1 (ru) | Способ лечения гинекологических заболеваний | |
WO2019087133A8 (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
EA201492238A1 (ru) | Композиция мизопростола | |
PE20142102A1 (es) | Metodos y composiciones para tratar enfermedades virales | |
UA86478U (ru) | Способ лечения синдрома хронической тазовой боли при генитальном эндометриозе | |
TH163150A (th) | รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์ | |
RU2019104078A (ru) | Комбинированная терапия для лечения рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |